Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Antengene Corporation Limited

Equities

6996

KYG039571008

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
0.97 HKD -.--% Intraday chart for Antengene Corporation Limited -1.02% -51.50%
May. 02 Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop MT
Apr. 29 Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop
MT
Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting
CI
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
AQ
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline
AQ
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
CI
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List
AQ
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List
MT
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
PR
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance
CI
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
AQ
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
CI
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma
AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
PR
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma
CI
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
AQ
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
PR
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
CI
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. News Antengene Corporation Limited